Publications by authors named "Donia Bahloul"
Introduction: This study assessed the comprehensive disease burden, the correlation among different patient-reported outcome measures (PROMs), and patient-reported treatment satisfaction with non-biologic agents in adult patients with prurigo nodularis (PN) in the United States.
Methods: A patient survey was conducted in the United States from June 30 to October 6, 2022, in patients with a self-reported diagnosis of PN. The survey included different PROMs assessing the symptoms and impacts of PN.
Healthcare Resource Utilization and Economic Burden of Prurigo Nodularis in the United States.
Dermatol Ther (Heidelb)
February 2025
Introduction: The impacts of prurigo nodularis (PN) on healthcare resource utilization (HCRU) and associated costs are unclear.
Methods: This retrospective, cross-sectional claims analysis (IQVIA PharMetrics Plus) compared HCRU and costs over 1 year in adults with PN versus matched controls (region, payer type, age, sex, year) from 2016 to 2019, and also in patients with PN receiving advanced versus localized/no therapy. For patients with data in multiple calendar years, 1 year was randomly selected.
Article Synopsis
- Prurigo nodularis (PN) is a chronic skin condition causing severe itching, and this study aimed to assess its impact on healthcare costs and resource use in Italy.
- The research analyzed data from 295 hospitalized PN patients and matched them with 590 non-PN individuals, revealing significant differences in comorbidities and healthcare resource consumption over a one-year follow-up period.
- PN patients had much higher healthcare costs, averaging €3847 compared to €711 for non-PN controls, primarily due to increased medication prescriptions, hospitalizations, and outpatient services.
Article Synopsis
- Bullous pemphigoid (BP) is a rare autoimmune skin disease primarily affecting older adults, leading to blistering lesions and a high mortality rate of 27-72%.
- A review analyzed 42 studies highlighting the clinical, humanistic, and economic impacts of BP, revealing that many patients experience severe symptoms, comorbidities, and significant mental health issues like depression and anxiety.
- The study underscored BP's considerable burden on patients, indicating longer hospital stays and higher healthcare costs, which are important for healthcare providers to consider in treatment planning.
Estimating the healthcare burden of Prurigo Nodularis in England: a CPRD database study.
J Dermatolog Treat
December 2024
Prurigo nodularis (PN) is a skin disease characterized by intensely itchy skin nodules and is associated with a significant healthcare resource utilization (HCRU). This study aimed to estimate the HCRU of patients in England with PN overall and moderate-to-severe PN (MSPN) in particular. This retrospective cohort study used data from the Clinical Practice Research Datalink and Hospital Episode Statistics in England.
View Article and Find Full Text PDFArticle Synopsis
- Prurigo nodularis (PN) is a skin condition marked by severe chronic itching, and its severity was measured using the Worst Itch Numeric Rating Scale (WI-NRS) in two phase 3 studies testing the drug dupilumab.
- The objective of these studies was to confirm the reliability and validity of the WI-NRS and to identify what constitutes a significant improvement in scores for patients suffering from moderate to severe PN.
- Results showed a successful assessment of WI-NRS, with high relevance and clarity for patients, and the study analyzed data from various trials conducted between December 2019 and August 2021, involving a total of 311 participants.
Article Synopsis
- Prurigo nodularis (PN) is a chronic skin condition that causes intensely itchy nodules, with limited research on its prevalence and treatment in England, particularly for moderate-to-severe cases.
- A retrospective cohort study using databases from 2007 to 2019 analyzed adult patients diagnosed with PN, categorizing them into moderate-to-severe PN (MSPN) or mild PN (MiPN) based on prescription records.
- Results showed that out of 8,933 patients, those with MSPN had significantly higher associations with conditions like atopic dermatitis and asthma, and there was an overall increase in both prevalence and incidence of PN during the study period.
Background: Prurigo nodularis (PN) is an intensely pruritic disease characterized by itchy nodules on the trunk/extremities; it is often accompanied by skin pain and sleep disruption with negative impacts on the quality of life (QoL). The patient-reported outcome (PRO) instruments, Worst Itch-Numeric Rating Scale (WI-NRS), Skin Pain-NRS, Sleep-NRS and Dermatology Life Quality Index (DLQI) have been psychometrically validated and the clinically meaningful within-patient improvement thresholds (responder definition) have been established through data pooled from the two Phase-3 trials (PRIME, NCT04183335 and PRIME2, NCT04202679) of dupilumab in adults with PN uncontrolled on topical therapies.
Objectives: To estimate the proportion of dupilumab-treated patients (vs.
Background: Prurigo nodularis (PN) also known as chronic prurigo, is a chronic inflammatory skin disease characterized by intensely itchy nodules/lesions which occur due to intensive scratching. PN management is, in part, based on clinician evaluations of PN lesions, which can be supported by clinician-reported outcomes (ClinRO) such as the Prurigo Activity and Severity (PAS) instrument. A 5-item version of PAS was included in recent phase-3 dupilumab PN trials (PRIME [NCT04183335]/PRIME2 [NCT04202679]).
View Article and Find Full Text PDF